Docket Number:11A-1030630
Inventor:Andrew H.-J. Wang, Kai-Fa Huang, Yan-Ping Shih
IP Status:TW I 532837
Abstract:
A number of bioactive hormone, peptides and secreted proteins have been identified to possess an N-terminal pyroglutamate (pGlu) residue which is required for their physiological activities. To date, the overproduction of these pGlu-modified proteins or peptides utilizing Escherichia coli or eukaryotic cells is still a challenging work. We designed a new method for production of N-terminal pGlu-modified proteins in vivo via intracellular self-cleavage of fusion tags by tobacco etch virus (TEV) protease and then immediate N-terminal cyclization of passenger target proteins by a bacterial glutaminyl cyclase. This design will facilitate the recombinant production of pGlu-modified protein drugs and drug-target proteins.
Fields of Application:
This design will facilitate the recombinant production of pGlu-modified protein drugs, drug-target proteins, and other proteins and peptides having potentials for clinical and bio-industrial applications.
Advantages when compared to the existing technologies:
A number of bioactive proteins and peptides have been identified to possess an N-terminal pyroglutamate (pGlu) residue which is required for their physiological activities. This N-terminal pGlu residue is a cyclization product of glutamine or glutamate residue catalyzed by the enzyme glutaminyl cyclase. To date, the overproduction of these pGlu-modified proteins or peptides utilizing Escherichia coli or eukaryotic cells is still a challenging work. Previously, to overproduce the N-terminal pGlu-modified proteins, the uncyclized protein samples were placed in 10-20 mM sodium phosphate buffers (pH 7-8) and then incubated at 37°C for 24 hours or incubated at 4°C for 2 weeks. However, the losses of recombinant samples were unavoidable owing to the degradation by contaminated proteases and/or aggregation during the long-period incubation. Here, we describe a new method for production of N-terminal pGlu-modified proteins in vivo via intracellular self-cleavage of fusion tags by tobacco etch virus (TEV) protease and then immediate N-terminal cyclization of passenger target proteins by a bacterial glutaminyl cyclase. To combine with the sticky-end PCR cloning strategy, this design allows the gene of target proteins to be efficiently inserted into the expression vector using two unique cloning sites (i.e., SnaB I and Xho I), and the soluble and N-terminal pGlu-containing proteins are then produced in vivo. This design will facilitate the production of protein drugs and drug target proteins that possess an N-terminal pGlu residue required for their physiological activities.
Contact Person:
對本技術有興趣,請於本處網頁廠商選項下(廠商需求與諮詢)網頁填寫資料,承辦人將跟您聯絡。
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Apply for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office, and the undertaker will contact you.
